Cargando…
Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wiley Publishing Asia Pty Ltd
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590675/ https://www.ncbi.nlm.nih.gov/pubmed/37731062 http://dx.doi.org/10.1111/1753-0407.13468 |
| _version_ | 1785124040456798208 |
|---|---|
| author | Hanhart, Joel Jeon, Sohee Tuuminen, Raimo |
| author_facet | Hanhart, Joel Jeon, Sohee Tuuminen, Raimo |
| author_sort | Hanhart, Joel |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10590675 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Wiley Publishing Asia Pty Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105906752023-10-23 Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered Hanhart, Joel Jeon, Sohee Tuuminen, Raimo J Diabetes Letter to the Editor Wiley Publishing Asia Pty Ltd 2023-09-20 /pmc/articles/PMC10590675/ /pubmed/37731062 http://dx.doi.org/10.1111/1753-0407.13468 Text en © 2023 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Hanhart, Joel Jeon, Sohee Tuuminen, Raimo Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered |
| title | Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered |
| title_full | Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered |
| title_fullStr | Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered |
| title_full_unstemmed | Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered |
| title_short | Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered |
| title_sort | should patient enrollment criteria for anti‐vegf phase iii trials be reconsidered |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590675/ https://www.ncbi.nlm.nih.gov/pubmed/37731062 http://dx.doi.org/10.1111/1753-0407.13468 |
| work_keys_str_mv | AT hanhartjoel shouldpatientenrollmentcriteriaforantivegfphaseiiitrialsbereconsidered AT jeonsohee shouldpatientenrollmentcriteriaforantivegfphaseiiitrialsbereconsidered AT tuuminenraimo shouldpatientenrollmentcriteriaforantivegfphaseiiitrialsbereconsidered |